Fluocinolone

Synalar (in FollicRX-type formulas)

Fluocinolone (Synalar (in FollicRX-type formulas)) is a healing & recovery research compound. Mid-potency topical corticosteroid. In hair formulas it's there to suppress the perifollicular inflammation that accompanies both androgenetic and inflammatory alopecia — it isn't doing the growing, it's removing an obstacle.

How Fluocinolone works

Mid-potency topical corticosteroid. In hair formulas it's there to suppress the perifollicular inflammation that accompanies both androgenetic and inflammatory alopecia — it isn't doing the growing, it's removing an obstacle.

Proposed benefits

Calming inflamed, itchy skin — a mid-potency topical steroid prescribed for steroid-responsive skin conditions, including inflammatory scalp disease. In compounded hair formulas it is there to take inflammation out of the way rather than to grow hair, and in the triple combination cream for melasma it is the anti-inflammatory third alongside hydroquinone and tretinoin.

Where to get Fluocinolone

The evidence for Fluocinolone

Graded by what exists behind each claim.

✅ Clinically validated

• Approved with extensive trial data as a topical corticosteroid, and as part of the triple combination cream (with hydroquinone and tretinoin) for melasma, where randomized trials show it outperforms any single agent.

📊 Correlative data

• Long clinical use. The well-documented real-world problem is duration: skin atrophy, telangiectasia and rebound on prolonged unsupervised use, which is why the triple combination is prescribed in courses.

🧪 Theoretical / extrapolated

• A mid-potency corticosteroid acting on glucocorticoid receptors to suppress inflammatory transcription.
• In melasma its role is to suppress the inflammation that drives pigmentation and to reduce the irritation from the other two actives — a supporting mechanism rather than a depigmenting one. The atrophy risk is the same glucocorticoid signaling acting on fibroblasts.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Fluocinolone actually does

Fluocinolone acetonide is four chemical modifications bolted onto a steroid nucleus, and each one buys a specific, nameable property. The molecule is 6α,9α-difluoro-16α-hydroxyprednisolone 16,17-acetonide. Read left to right, that is the whole design.

The prednisolone core — the Δ1 double bond. Adding a double bond between carbons 1 and 2 of hydrocortisone gives prednisolone: roughly four times the glucocorticoid potency and less salt retention. This is the base every potent topical steroid is built on.

9α-fluoro — the potency step, and it comes with a problem. A fluorine at the 9α position is strongly electron-withdrawing, which raises the acidity of the neighboring 11β-hydroxyl and tightens binding to the glucocorticoid receptor. It also raises mineralocorticoid activity sharply — 9α-fluorohydrocortisone is fludrocortisone, which is used as a mineralocorticoid. So this single change makes the molecule much more potent and much more sodium-retaining at once.

6α-fluoro — the correction. A second fluorine at 6α further increases glucocorticoid potency while working against the mineralocorticoid liability the 9α fluorine introduced. Two fluorines is not twice one fluorine; they are doing different jobs.

The 16,17-acetonide — and this is the modification that makes it a topical drug rather than a systemic one. Locking the 16α and 17α hydroxyls into a cyclic ketal with acetone does two things simultaneously: 16α-substitution abolishes what remains of the mineralocorticoid activity, and the acetonide ring is sharply lipophilic. A lipophilic steroid partitions into the stratum corneum and forms a reservoir there, which is why acetonides — fluocinolone, triamcinolone, fluocinonide — dominate topical dermatology and are almost absent from oral steroid cabinets.

What the receptor then does. The steroid crosses the keratinocyte membrane, binds the cytosolic glucocorticoid receptor, and the complex moves to the nucleus, where it both transactivates anti-inflammatory genes and transrepresses the NF-κB- and AP-1-driven inflammatory program. In alopecia specifically, the proposed action is reducing the CD8+ T-cell-mediated immune attack on the hair follicle Gregoire 2025. Note what that is and is not: it removes an obstacle to growth. It does not grow hair. The card is right about this and it is worth restating — in a compounded hair formula, the steroid is not the active, it is the thing that stops the immune system undoing the active.

And here is the card’s own internal contradiction, which matters clinically. The mechanism line calls this a ‘mid-potency topical corticosteroid’; the dose line says 0.01%. Fluocinolone acetonide is marketed at 0.01%, 0.025% and 0.2%, and in the seven-class US potency system — which is ranked by the skin-blanching vasoconstrictor assay, not by the name of the molecule — those three strengths of the same drug land in different classes, from the mild end up to potent. 0.01% is the bottom of that range, not the middle. Saying ‘fluocinolone’ on an ingredient list is not a potency statement.

Cell, rodent, human — and where it stops

Step one, the class in humans, and the single most useful sentence about this compound is in it. A narrative review of local corticosteroids in alopecia areata — a condition affecting about 2% of the population worldwide — states that topical corticosteroids are safe and well tolerated with moderate efficacy in mild disease, that recurrence is common after treatment cessation, and that intralesional steroids are more effective than topical ones given their ability to penetrate the dermis, where the hair follicle resides Gregoire 2025.

Read that last clause slowly, because it is the whole problem with the product this ingredient appears in. The same drug class works better when it is injected, and the stated reason is depth. A compounded topical solution for scalp hair is being asked to do the thing the review says topical delivery does worst.

Step two, the one randomized trial with fluocinolone in it by name. 53 Chinese patients with moderate-to-severe melasma randomized to a generic triple combination cream (fluocinolone acetonide + hydroquinone + tretinoin), branded TRI-LUMA, or placebo, once daily for 8 weeks. Efficacy was 52.2% for the generic against 57.1% for the brand. Adverse events occurred in 69.6% and 90.5% of the two active arms and 0% of the placebo arm Hu 2025. The fluocinolone strength in that formulation is 0.01% — exactly what a hair formula uses.

Those adverse-event numbers are the finding. Nine in ten people on the branded triple cream had a treatment-emergent adverse event within eight weeks, against none on placebo. Some of that belongs to the tretinoin and the hydroquinone — and the steroid is in the formula precisely because those two irritate. That is the honest role of 0.01% fluocinolone in a combination product: it is not the therapy, it is the thing that makes the therapy tolerable.

Step three, the systemic-exposure ceiling, borrowed from a much stronger steroid. Clobetasol propionate 0.05% — a class-I superpotent steroid, several classes above fluocinolone 0.01% — causes HPA-axis suppression at doses as low as 2 g per day. In an 88-patient phase 2a study of moderate-to-severe psoriasis dosed twice daily for 28 days, the proportion with an abnormal ACTH stimulation test (cortisol ≤ 18 µg/dL) at day 28 was 30.0% on 0.05% cream and 20.7% and 17.2% on two 0.025% formulations, p = 0.320 Sidgiddi 2021. Nearly a third of people on a superpotent steroid at psoriasis-scale coverage had a measurably blunted adrenal response inside a month.

Step four, the failure mode of long use. Topical steroid withdrawal is described as a rebound following discontinuation of prolonged use of mid-to-high-potency topical corticosteroids: red, burning, itchy, painful, peeling and cracking skin, sleep disturbance, and secondary bacterial infection with heavy Staphylococcus aureus colonization in a majority of affected people. There are no definitive diagnostic criteria, it is often misdiagnosed as a flare of the underlying condition or as contact allergy, and management centers on gradual tapering before complete discontinuation Maskey 2025. That is the evidence behind ‘cycle off periodically’ on the card — and note the tapering point, because cycling abruptly is the opposite of what the literature advises.

The obstacles, named one at a time. (1) No trial of the product exists. There is no published randomized trial of any compounded fluocinolone-containing hair formula; the evidence is for the class in alopecia areata Gregoire 2025 and for the molecule in melasma Hu 2025, neither of which is androgenetic alopecia. (2) The component has never been isolated. These formulas contain minoxidil, sometimes finasteride, sometimes retinoids; nobody has run the formula with and without the steroid. (3) Depth. The review says intralesional beats topical because of penetration Gregoire 2025, and nobody has measured what a scalp solution delivers to the bulb. (4) Duration. Every trial cited here runs 4 to 8 weeks; hair formulas are run for years. (5) The condition treated is different. Alopecia areata is autoimmune and the steroid targets its mechanism directly; androgenetic alopecia has perifollicular microinflammation but is not an autoimmune attack, so the rationale is weaker in exactly the population these formulas are sold to.

Fluocinolone pharmacokinetics — how much of it actually gets in

The catalog says ‘Local’. That is right, and the arithmetic under it decides whether the risk on this page is systemic or local — which is the only question that matters for a steroid someone plans to use for years.

The applied dose, computed. 0.01% is 0.1 mg per gram, or 100 µg/g. A typical scalp application is 1 mL of solution over the affected area; if that area is 500 cm² — roughly a vertex plus frontal region — the applied dose is 100 µg total, about 0.2 µg per cm². Cross-check it the other way: one fingertip unit is 0.5 g and covers about 300 cm², which at 0.01% is 50 µg over 300 cm², or 0.17 µg/cm². The two methods agree, which means the number is real rather than an artefact of the assumption.

Now put it against the exposure that actually suppresses an adrenal gland. Clobetasol 0.05% suppresses the HPA axis at 2 g/day Sidgiddi 2021, which is 1,000 µg/day of a class-I superpotent steroid. A scalp dose of 0.01% fluocinolone is 100 µg/day of a molecule several potency classes weaker. That is a ten-fold lower mass of a substantially weaker drug over a smaller area — the scalp is roughly 3–4% of body surface, against the 10–20% a psoriasis patient treats. Systemic suppression from that regimen is implausible, and saying so plainly is more useful than a generic warning. The risk that actually applies is local, it is driven by duration and occlusion rather than by dose, and it is the risk nobody quantifies because it does not show up on a blood test.

What raises the number, and by how much. Occlusion — a cap, a wrap, an overnight oil, or simply a dense vehicle — increases corticosteroid absorption several-fold, and it is the single variable most likely to convert this arithmetic from safe to not. Inflamed or eroded skin has a broken barrier and absorbs far more than intact skin. And formulation matters as much as concentration: in a directly comparable topical, changing only the vehicle produced 4.60-fold higher human skin flux and a 529% increase in dermal deposition at the same drug percentage Subedi 2022.

What degrades it. In the skin, very little — the acetonide is the stable form and the stratum corneum acts as a reservoir that releases drug over hours to days. What is absorbed is cleared hepatically by cytochrome P450 oxidation and by glucuronide and sulfate conjugation, then excreted renally. Fluocinolone acetonide is small — about 452 Da — which places it right at the edge of the 500 Dalton rule for skin penetration Bos 2000, and unlike the cosmetic peptides elsewhere in this catalog it genuinely crosses.

The oral barrier, for completeness. Glucocorticoids given by mouth undergo substantial gut-wall and hepatic first-pass metabolism, which is one reason topical steroids are never dosed that way; there is no oral fluocinolone product.

The injectable comparator, which is the one that matters here. Intralesional corticosteroid injection is the same drug class delivered past the barrier, and it is more effective than topical steroid in mild-to-moderate alopecia areata precisely because it reaches the dermis where the follicle sits; its limit is pain during the procedure rather than efficacy Gregoire 2025. That is the cleanest available proof that topical delivery to a hair follicle is the weak link, and it is stated in the review rather than inferred.

What would have to be true, and how you would know it was not

Four predictions, and two of them are blood tests that would settle the systemic-versus-local question that every steroid warning leaves vague.

1. A morning cortisol should NOT move on 0.01% over a scalp — and if it does, something is wrong with the formula. Draw an 8 a.m. serum cortisol at baseline and again at 8 weeks. The prediction, from the arithmetic above, is no change: 100 µg/day of a low-potency steroid over 3–4% of body surface is an order of magnitude below the 2 g/day of superpotent steroid that suppresses the axis Sidgiddi 2021. This is the prediction most likely to be right and it is worth making anyway, because a morning cortisol that falls below the reference range in that setting means the exposure is not what the label says — a stronger compounded concentration, a far larger treated area, or occlusion.

2. If the formula is stronger than 0.01% or run under occlusion, the test that matters is a stimulation test, not a random draw. The endpoint used in the psoriasis study was an ACTH stimulation test with a threshold of cortisol ≤ 18 µg/dL, which flagged 30.0% of people on clobetasol 0.05% Sidgiddi 2021. A single random cortisol has too wide a diurnal spread to detect partial suppression; the stimulation test is the one that does. Nobody using a compounded hair formula has ever been reported to have had one.

3. The local read-out is the one that will actually change, and it is free. What to watch: the treated skin itself — shine, translucency, visible fine vessels (telangiectasia), and easy bruising at the application site. Photograph one fixed patch at a fixed distance under the same light, monthly. How long before it means anything: atrophy from a low-potency steroid is a months-to-years process, not a weeks one, so nothing seen at 4 weeks is atrophy and anything seen at 3 months on 0.01% suggests the compounded strength is not what the label claims. What will fool you: scalp skin already looks shinier where hair is thinner, and the alcohol and propylene glycol in most hair vehicles cause redness and scaling that look exactly like early steroid damage and are not.

4. The prediction that argues against the product: stopping should make things worse, and that is not evidence the drug was working. Recurrence after cessation is explicitly common with topical steroids in alopecia areata Gregoire 2025, and topical steroid withdrawal produces a rebound that is routinely misdiagnosed as a flare of the underlying condition Maskey 2025. So the single most persuasive experience a user can have — ‘I stopped and it got worse, so it must have been helping’ — is exactly the observation the literature says will mislead you. The way to test it is to taper rather than stop Maskey 2025, which separates a genuine loss of benefit from a withdrawal rebound.

What nobody has tested yet

Four experiments, and the first one is embarrassing in how easy it would be.

1. Nobody has run the hair formula with and without the steroid. Compounded scalp formulas pair fluocinolone with minoxidil and often finasteride or a retinoid, and no published study isolates the corticosteroid’s contribution. A three-arm, 24-week trial — full formula, formula minus fluocinolone, vehicle — would tell every buyer of these products whether they are taking a steroid for a reason. It has never been run.

2. Nobody has measured what a scalp solution delivers to the follicular bulb. The class review attributes the superiority of intralesional over topical steroid to dermal penetration Gregoire 2025, but no study reports the concentration a topical solution achieves at bulb depth. It is measurable — punch biopsies at fixed times after application, assayed by mass spectrometry — and the answer would determine whether topical steroid on a scalp is pharmacology or theater.

3. Nobody has tested whether cycling prevents anything. ‘Cycle off periodically’ is universal advice with no trial behind it, and the withdrawal literature actually argues for tapering rather than stopping Maskey 2025 — the opposite of an abrupt on-off cycle. A comparison of 12 weeks continuous against a 4-weeks-on, 2-weeks-off schedule, scored by standardized photography and by ultrasound-measured skin thickness, is a small study nobody has done, and it would settle the most widely repeated piece of advice in this whole category.

4. Nobody has checked the HPA axis in a real user of these formulas. The suppression data comes from psoriasis patients using superpotent steroid over large areas Sidgiddi 2021. The arithmetic above predicts a comfortable margin for a scalp at 0.01% — but compounded strengths vary, occlusion is common, and some people also use topical steroid elsewhere on the body. Twenty morning cortisols from long-term users would either confirm the margin or find the outlier, and either result is new information.

Fluocinolone — its own safety story, not its class's

The shared block on this page is a healing-and-recovery safety profile written for injectable peptides. None of it is a topical corticosteroid’s risk story. A topical steroid has four specific harms, they are all local except one, and they are all functions of potency multiplied by duration multiplied by occlusion.

1. Skin atrophy and telangiectasia are the dose-limiting toxicity, and duration is the driver. Glucocorticoids suppress fibroblast collagen synthesis and keratinocyte proliferation, which thins epidermis and dermis; the visible results are shiny translucent skin, prominent fine vessels, easy bruising and stretch marks. On a class-VI 0.01% preparation over a scalp, this is a months-to-years risk rather than a weeks one — but hair formulas are run for years, which is exactly the timescale where it lands. Atrophic skin also absorbs more drug, so the process accelerates itself.

2. Topical steroid withdrawal is the specific hazard of indefinite use, and it is poorly recognized. Red, burning, itching, painful, peeling and cracking skin after stopping prolonged mid-to-high-potency use; sleep disturbance from the itch; secondary Staphylococcus aureus colonization in a majority; no definitive diagnostic criteria; and frequent misdiagnosis as a flare of the underlying condition or as contact allergy Maskey 2025. On a scalp being treated for hair loss, that misdiagnosis has an obvious and expensive form: the person concludes the hair loss is accelerating and increases the dose.

3. HPA-axis suppression, put in proportion rather than waved at. It is real, it is measurable, and at superpotent strength it happens fast — 30.0% abnormal ACTH stimulation tests at 28 days on clobetasol 0.05%, with suppression documented at doses as low as 2 g/day Sidgiddi 2021. At 0.01% over a scalp the computed exposure is roughly a tenth of that mass of a much weaker molecule, so the honest statement is that this is a real class risk that this particular regimen is very unlikely to reach — unless the compounded strength is higher than stated, the area is much larger, or occlusion is used.

4. Facial and periocular spread, which is where scalp formulas actually cause trouble. Solutions applied to a hairline run down the forehead and around the eyes. Facial skin is thin and absorbs far more than scalp; the characteristic consequences are perioral dermatitis, steroid rosacea and periocular atrophy, and they occur at potencies that are harmless on a trunk. This is the most likely adverse event from a compounded hair product and it is almost never mentioned.

5. What the record actually contains. The only randomized data with fluocinolone by name in this catalog’s context is an 8-week melasma trial in which 90.5% of the branded-cream arm and 0% of the placebo arm had a treatment-emergent adverse event Hu 2025, and a narrative review reporting the class as ‘safe and well tolerated’ in mild alopecia areata Gregoire 2025. Both are true and they are about different products at different durations. There are 0 published safety data on any compounded fluocinolone hair formula, which is not the same as those products being safe — it is the same absence of a study in which harm could have been recorded.

Sources read for this page

• Gregoire S, et al. Local Corticosteroids for Alopecia Areata: A Narrative Review. Dermatology and Therapy 2025 · PMID 40323545
• Hu H, et al. Efficacy and Safety of Generic Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream Compared With TRI-LUMA for the Treatment of Moderate-To-Severe Melasma in Chinese Patients: A Randomized, Single-Center, Placebo-Controlled Trial. Journal of Cosmetic Dermatology 2025 · PMID 40296512
• Sidgiddi S, et al. Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. Dermatology and Therapy 2021 · PMID 34453262
• Maskey AR, et al. Breaking the cycle: a comprehensive exploration of topical steroid addiction and withdrawal. Frontiers in Allergy 2025 · PMID 40230788
• Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 2000 · PMID 10839713
• Subedi L, et al. Preparation of topical bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia. Drug Delivery 2022 · PMID 35040730

Fluocinolone — safety, predicted from mechanism

Fluocinolone — interference & stacking

Bloodwork to run alongside Fluocinolone

Baseline first, then again at 8–12 weeks.

The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.

Check results you already have → · All 103 markers A–Z

Fluocinolone — frequently asked questions

What Fluocinolone is used for

Fluocinolone appears under 1 goal in the goal router.

Related Healing & Recovery compounds

← Explore the full Protocol Vault

↑ Back to on this page